Acasti Pharma (NASDAQ:ACST) Releases Quarterly Earnings Results, Beats Estimates By $0.30 EPS

Acasti Pharma (NASDAQ:ACSTGet Free Report) announced its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.30, Yahoo Finance reports.

Acasti Pharma Stock Down 1.8 %

NASDAQ ACST opened at $3.24 on Monday. The company has a market capitalization of $30.46 million, a price-to-earnings ratio of -0.65 and a beta of 1.61. Acasti Pharma has a twelve month low of $1.72 and a twelve month high of $3.84. The stock has a fifty day simple moving average of $2.94 and a 200 day simple moving average of $2.91.

Acasti Pharma Company Profile

(Get Free Report)

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.

See Also

Earnings History for Acasti Pharma (NASDAQ:ACST)

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with's FREE daily email newsletter.